0001213900-23-057863.txt : 20230718 0001213900-23-057863.hdr.sgml : 20230718 20230718161504 ACCESSION NUMBER: 0001213900-23-057863 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230718 FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Biotechnologies Ltd CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38370 FILM NUMBER: 231094410 BUSINESS ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20190620 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Biotechnologies Ltd. DATE OF NAME CHANGE: 20190619 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20150122 6-K 1 ea181965-6k_collplant.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2023

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842 and 333-271320) and Form F-3 (File No. 333-228054, 333-238731 and 333-269087), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On July 18, 2023, CollPlant Biotechnologies Ltd. (the “Company”) convened an annual and extraordinary general meeting of shareholders (the “Meeting”) at which the Company’s shareholders approved each of the five proposals brought before the Meeting in accordance with the majority required for each proposal.

Each of those proposals was described in the Notice and Proxy Statement with respect to the Company’s Annual and Extraordinary General Meeting of Shareholders, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on June 8, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.

Date: July 18, 2023	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer